The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.
M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.
With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.
HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.
A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.
The company will provide further information in due course.
As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.
Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone.
We use cookies on our website.Some of them are essential, while others help us to improve this website and your experience.
Technically necessary tools that enable essential services and basic functions, including identity verification, service continuity and site security. This option cannot be denied.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Speichert die aktuelle PHP-Session.
Third-party content, e.g. stock widgets, are blocked by default. If third-party cookies are accepted, access to this content no longer requires manual consent.
We use the TradingView to display stock charts. This provider uses additional cookies to analyze its services.
By using this website, you consent to the use of cookies. You can find detailed information on the use of cookies on this website in the data protection declaration.
Menu
